Copperwynd Financial LLC Purchases 487 Shares of Merck & Co., Inc. $MRK

Copperwynd Financial LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 2.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 21,144 shares of the company’s stock after acquiring an additional 487 shares during the period. Copperwynd Financial LLC’s holdings in Merck & Co., Inc. were worth $1,674,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of MRK. Armstrong Fleming & Moore Inc bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $628,000. Tectonic Advisors LLC raised its stake in shares of Merck & Co., Inc. by 26.2% during the 2nd quarter. Tectonic Advisors LLC now owns 101,656 shares of the company’s stock worth $8,047,000 after purchasing an additional 21,124 shares in the last quarter. Fulton Breakefield Broenniman LLC raised its stake in shares of Merck & Co., Inc. by 3.1% during the 2nd quarter. Fulton Breakefield Broenniman LLC now owns 7,948 shares of the company’s stock worth $629,000 after purchasing an additional 236 shares in the last quarter. Allegiance Financial Group Advisory Services LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $473,000. Finally, Beaumont Asset Management L.L.C. raised its stake in shares of Merck & Co., Inc. by 2.2% during the 2nd quarter. Beaumont Asset Management L.L.C. now owns 8,313 shares of the company’s stock worth $658,000 after purchasing an additional 179 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MRK shares. Morgan Stanley dropped their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday. Finally, Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $104.31.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $86.39 on Thursday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $111.58. The company has a market cap of $215.78 billion, a P/E ratio of 13.31, a P/E/G ratio of 0.90 and a beta of 0.37. The business has a fifty day simple moving average of $83.15 and a 200 day simple moving average of $81.56.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th were paid a $0.81 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.8%. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.